Ticker	Current Price	Change	Graph
IBB	110.47	0.68 (0.62%)
XBI	83.38	0.98 (1.19%)

Deals, Insiders

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

FDA, Regulatory, Setbacks

Immunomedics must endure another delay as FDA rejects cancer drug citing manufacturing issues

Cancer, Results, Setbacks

Lilly's approved cancer drug Lartruvo fails confirmatory study, setting the stage for withdrawal of regulatory endorsement

Latest

Safety concerns lead to a split FDA panel vote on Sanofi/Lexicon diabetes drug →

Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism →

Novartis teams up with Oxford researchers to crunch big data into clinical insights →

Scoop: Forma axes discovery biology team as part of a broader reorganization →

With J&J deal to assess value of Apple watch in atrial fibrillation, tech giant fortifies its foray into healthcare →

NIH researchers report animal model validation for stem cell-based approach to advanced dry AMD →

Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days →

UPDATED: Zafgen has something to cheer as diabetes drug makes the cut in PhII study →

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep? →

Top News

Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt

Amber Tong

Second time's a charm for osteoporosis drug from Amgen, UCB as FDA panel grants its blessing

Natalie Grover

FDA revises draft guidance on rare disease drug R&D

Zachary Brennan - RAPS

Aptinyx shares crater as lead drug fails in PhII neuropathic pain study

Natalie Grover

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug

Amber Tong

More news

Protocols

Quick hits from around the biopharma web

Jan 18

Tyme flops on cancer drug data; Lilly IND filing triggers $8M payment to partner Zymeworks

Jan 17

Bayer axing 665 workers at US campus; NASH biotech pumps up share price with an ‘interim’ snapshot

Jan 16

AstraZeneca signs deal to promote product made in China — in mainland China; Israeli deep brain stimulation co Brainsway sets stage for $30M Nasdaq IPO

Jan 15

Seres promotes CFO Eric Shaff to succeed Pomerantz as CEO; Exelixis' Cabometyx bags US approval for liver cancer

More Protocols

Peer Review

Weekly biopharma careers news report

Jan 18

John Mendlein leaves Moderna for Flagship; Paul Sekhri to steer first xenotransplantation trials as eGenesis CEO

Jan 14

CMO Sean Bohen joins exodus at AstraZeneca during a major R&D leadership overhaul

Jan 11

Ironwood recruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant

Jan 10

Roche exec Pearl Huang rejoins biotech as CEO of Cygnal — Flagship's bet on 'exoneural biology'

More peer review

Premium

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

Bioregnum

The view from John Carroll

Jan 17

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

Jan 16

Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS. And the timing couldn't be worse

Jan 11

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

Jan 2

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

More opinion

Marco

Hot BioTwitter bot - last updated ago

Most Viral

The Seven Trends That Define The Future of IVF

Forbes a day

Imbruvica flop puts pressure on pancreatic pipeline

Evaluate.com a day

15 Studies That Challenged Medical Dogma in 2018

MedScape Eric J. Topol a day

Payouts push professors towards predatory journals

Nature a day

Scientist Who Edited Babies' Genes Is Likely to Face Charges in China

New York Times a day

Trump’s Big Missed Opportunity: Medicare For All

Pink Sheet a day

Action not words needed over biggest public health failure of our time: pneumonia | Larry Elliott

The Guardian Larry Elliott a day

Classes of Immunotherapy Under Investigation in Multiple Myeloma

OncLive a day

The FDA is threatening to take e-cigarettes off the market

Yahoo a day

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

OncLive a day

Latest

Evaluate.com

Imbruvica flop puts pressure on pancreatic pipeline

Pharmaphorum

GSK's chairman Sir Philip Hampton steps down - Pharmaphorum

New York Times

Scientist Who Edited Babies' Genes Is Likely to Face Charges in China

Pharmaphorum

JP Morgan Healthcare: where science, tech and finance collide - Pharmaphorum

Yahoo

The FDA is threatening to take e-cigarettes off the market

Harvard Blogs

Letter in response to Jan. 17 article in The New York Times | David Reich Lab

OncLive

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

OncLive

Classes of Immunotherapy Under Investigation in Multiple Myeloma

MedScape

15 Studies That Challenged Medical Dogma in 2018

Vjhemonc

Tagraxofusp for BPDCN gives encouraging results

Hot This Week

1

GlobeNewswire News Room

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

2

ENDPOINTS NEWS

Gottlieb, Marks detail plans to advance development of cell and gene therapies

3

STAT

Tyme Technologies misleads with cancer drug data release - STAT

4

STAT

FDA rejects Immunomedics breast cancer drug, extending long drought - STAT

5

ENDPOINTS NEWS

May the candle burn forever: Polite reminders about the JPMorgan confab

6

New York Times

New York Confronts Its Worst Measles Outbreak in Decades

7

STAT

New details revealed about Purdue's marketing of OxyContin- STAT

8

BusinessWire

Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities

9

Eli Lilly and Company

Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO® | Eli Lilly and Company

10

Xconomy

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

Immunomedics must endure another delay as FDA rejects cancer drug citing manufacturing issues

Lilly's approved cancer drug Lartruvo fails confirmatory study, setting the stage for withdrawal of regulatory endorsement

Latest

Safety concerns lead to a split FDA panel vote on Sanofi/Lexicon diabetes drug →

Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism →

Novartis teams up with Oxford researchers to crunch big data into clinical insights →

Scoop: Forma axes discovery biology team as part of a broader reorganization →

With J&J deal to assess value of Apple watch in atrial fibrillation, tech giant fortifies its foray into healthcare →

NIH researchers report animal model validation for stem cell-based approach to advanced dry AMD →

Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days →

UPDATED: Zafgen has something to cheer as diabetes drug makes the cut in PhII study →

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep? →

Top News

Protocols

Peer Review

Premium

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

Bioregnum

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password